General AML

EHA 2019 | Could the first-in-class anti-CD47 antibody HU5F9-G4 be a promising treatment strategy?


At the 24th Congress of the European Hematology Association (EHA), David Sallman from the Moffitt Cancer Center, Tampa, US, discusses if the first-in-class anti-CD47 antibody HU5F9-G4 (5F9) could be a promising treatment strategy for patients with acute myeloid leukemia (AML).
5F9 is a first-in-class IgG4 antibody that targets CD47 to enable phagocytosis. David Sallman discusses the initial results from the phase Ib trial investigating 5F9 alone, or with azacitidine, in patients with high-risk AML and myelodysplastic syndrome (MDS). The early data indicate that 5F9 is well-tolerated, with promising activity in patients with AML/MDS, and that adding 5F9 to cytotoxic agents may be a promising treatment strategy.